Skip to content

Conformal Medical Secures $85M in Series C Financing

 Funding to Support U.S. Pivotal Trial of CLAAS® Stroke Prevention Technology 


 NASHUA, N.H. – Aug 6, 2020 – Conformal Medical, Inc., a medical device company focused on reducing stroke in patients with atrial fibrillation (AFib), today announced it has secured $85 million in Series C financing. The financing syndicate included participation from new investors Fidelity Management & Research Company LLC and an undisclosed strategic investor, as well as Catalyst Health Ventures (CHV) and many returning Series A and B investors. Funds will be used to support the company’s U.S. pivotal trial of its novel CLAAS® Technology, a next-generation solution for sealing the left atrial appendage in patients with atrial fibrillation. 

Read more